Gerry Christopher 4

What Happened Gerry Christopher, President and Principal Executive Officer of Sensei Biotherapeutics (SNSE), was granted a stock option award covering 220,000 shares on June 10, 2026. The Form 4 reports this as a derivative "award" (no cash paid at grant). The exercise price is set equal to the closing price of Sensei common stock on April 10, 2026 (the board-approved grant date), but the filing does not state a dollar-per-share exercise price in the transaction line.

Key Details

• Transaction date: June 10, 2026 (Form 4 filed June 12, 2026; appears timely).
• Award type: Stock option grant (derivative); 220,000 shares reported as acquired (code A).
• Reported cash paid: $0 (standard for option grants).
• Exercise price: Equals the closing price on April 10, 2026 (per footnote); exact dollar amount not listed in the transaction line of the supplied details.
• Vesting: 25% vests on April 10, 2027, then the remainder vests in 36 equal monthly installments, fully vesting April 10, 2030, subject to continuous service (per footnote).
• Shares owned after transaction: Not disclosed in the supplied transaction details.
• Approval: Grant approved by the Board on April 10, 2026, conditioned on stockholder approval of the 2026 Equity Incentive Plan, which was obtained on June 10, 2026.

Context This filing reports a standard executive equity grant rather than a purchase or sale. Grants indicate potential future ownership and dilution if options are exercised; they do not by themselves involve cash changing hands or immediate market activity. The vesting schedule ties the economic benefit to continued service through April 2030.